THURSDAY, 30th JUNE 2016

MULTIPLE
MYELOMA
2016
Perspectives for a
paradigm change
University Magna Græcia, Catanzaro (Italy)
30th June - 2nd July 2016
Educational Workshop
Innovation meets medical oncology
University Magna Græcia - 30th June 2016
Congress Presidents
Pierfrancesco Tassone - Angelo Vacca
SCIENTIFIC PROGRAM
THURSDAY, 30th JUNE 2016
8.30 Registration of participants
Educational Workshop
INNOVATION MEETS MEDICAL ONCOLOGY
8.50Welcome address and orientation
Pierfrancesco Tassone (Catanzaro - I), Angelo Vacca (Bari - I)
Chairpersons: S
alvatore Palazzo (Cosenza - I), Franco Silvestris (Bari - I),
Pierosandro Tagliaferri (Catanzaro - I)
FRIDAY, 1st JULY 2016
Workshop 3 - New insights in the biology of multiple myeloma
Chairpersons: Federico Caligaris-Cappio (Milan - I), Antonino Neri (Milan - I) 9.00New biological achievements in bone disease
Nicola Giuliani (Parma - I)
9.20Clonal evolution of multiple myeloma
Nizar Bahlis (Calgary - CDN)
9.40 AP-1 transcription factors
Klaus Podar (Heidelberg - D)
9.00Genomics opens a new scenario for cell cycle and mTOR inhibitors: everolimus 10.00IAP antagonists as immunomodulators in multiple myeloma
Marta Chesi (Scottsdale - USA)
and beyond
Carlo Capalbo (Rome - I)
10.30Salvatore Venuta Memorial Lecture
Perspectives for a paradigm change
9.15An expanded view on anti-angiogenetic agents: bevacizumab, aflibercept,
Chairpersons: P
ierfrancesco Tassone (Catanzaro - I), Angelo Vacca (Bari - I)
ramucirumab, sunitinib and beyond
Speaker:
Kenneth
C. Anderson (Boston - USA)
Nicola Silvestris (Bari - I)
9.30Prediction meets genetics: PARP inhibition on clinical stage
Sergio Rizzo (Palermo - I)
SATURDAY, 2nd JULY 2016
11.20 - 11.40 Coffee break
Workshop 8 - Smoldering myeloma and plasma cell dyscrasias
Chairpersons: Emanuele Angelucci (Cagliari - I), Franco Dammacco (Bari - I)
9.00Biology and treatment of smoldering myeloma
Francesco Di Raimondo (Catania - I)
9.20Extramedullary myeloma
Aldo Roccaro (Brescia - I)
9.40Plasma cell leukemia
Pellegrino Musto (Rionero in Vulture - I)
10.00 - 10.20 Coffee break
Workshop 9 - Developmental new drugs
Chairpersons: Stefano Molica (Catanzaro - I), Francesco Trapasso (Catanzaro - I)
10.20IMiDs plus anti-CS1
Alida Dominietto (Genoa - I)
10.40 Immunotherapy of multiple myeloma: new perspectives
Martin Gramatzki (Kiel - D)
9.45Immune check-point inhibitors: revolution for cure
Pierpaolo Correale (Siena - I)
Workshop 4 - Translational approaches for innovative therapeutic strategies
Chairpersons: Pierosandro Tagliaferri (Catanzaro - I),
11.00IMiDs in multiple myeloma: is it all about MYC and its enhancer?
Pierfrancesco Tassone (Catanzaro - I)
Paola Neri (Calgary - CDN)
10.00 Exosomes as bio-markers in immunotherapy
Marco Tucci (Bari - I)
11.40Ex-vivo 3D and in vivo bone-derived co-culture model for new drug screening
Monica Engelhardt (Freiburg - D)
11.20E2F and BET Bromodomains as potential targets in multiple myeloma
Mariateresa Fulciniti (Boston - USA)
10.15 General discussion
12.00Targeting non-coding RNAs: a new clinical paradigma
Marco Rossi (Catanzaro - I)
11.40New Proteasome inhibitors: carfilzomib, ixazomib and beyond
Antonia Reale (Bari - I)
12.20Cell and gene based IMPs for multiple myeloma treatment
Farzin Farzaneth (London - UK)
12.00Targeting the Wnt/beta-catenin/BCL9 transcriptional complex for multiple
myeloma therapy
Ruben D. Carrasco (Boston - USA)
10.30 - 10.45 Coffee break
10.45Androgen-responsiveness, a new path of opportunities
Michele Caraglia (Naples -I)
11.00 New opportunities from marine derived compounds: trabectedin, eribulin
and beyond
Eugenio Donato Di Paola (Catanzaro - I)
12.40Keynote Lecture
Role of non coding RNAs in multiple myeloma
Chairperson: G
iovanni Morrone (Catanzaro - I)
Speaker: Carlo Croce (Columbus - USA)
11.15PI3K-inhibitors: new drugs for promising targets
Christian Rolfo (Antwerp - B)
13.30 - 14.00 Lunch
11.30 Trastuzumab, pertuzumab, trastuzumab emtansine, cetuximab, panitumumab:
still an evolving scenario?
Francesco Pantano (Rome - I)
11.45 New strategies for the treatment of bone metastases
Sergio Baldari (Messina - I)
12.00Thrombotic risk prevention in cancer patients: a new scenario
Candida Mastroianni (Cosenza - I)
12.15General discussion and conclusions
Workshop 5 - Diagnostic and prognostic factors
Chairpersons: Massimo Gentile (Cosenza - I), Angelo Vacca (Bari - I)
14.00Waldenström macroglobulinemia
Steven Treon (Boston - USA)
12.20Mechanisms underlying genomic instability and their translational significance
Masood Shammas (Boston - USA)
12.40Synthetic lethal approaches exploiting DNA Damage
Giovanni Tonon (Milan - I)
13.00Relevance of clinical response on patient survival:
a critical issue in drug development
Ralph Wäsch (Freiburg - D)
13.20 Closing Remarks
Pierfrancesco Tassone (Catanzaro - I), Angelo Vacca (Bari - I)
14.20AL amyloidosis: pathogenetic role of free light chains
Giampaolo Merlini (Pavia - I)
14.40Diagnostic and prognostic role of light and heavy chain test
Giovanni Palladini (Pavia - I)
12.30 - 13.30 Lunch
15.00Minimal residual disease
Lucio Catalano (Naples - I)
MULTIPLE MYELOMA 2016 - PERSPECTIVES FOR A PARADIGM CHANGE
15.20Kidney impairment
Daniele Derudas (Cagliari - I)
14.00Welcome address - Chancellor Magna Graecia University - Aldo Quattrone (Catanzaro - I) 15.40Risk models as a guide to treatment
Dirk Hose (Heidelberg - D)
14.10Welcome speech and orientation
Workshop 6 - Upfront therapy
Pierfrancesco Tassone (Catanzaro - I), Angelo Vacca (Bari - I)
Chairpersons: F rancesco Iuliano (Rossano - I), Antonio Palumbo (Turin - I)
14.20Opening Lecture
16.00First line therapy in young patients: is auto-SCT always the standard of care?
New advances in molecular classification and therapy of multiple myeloma
Hermann Einsele (Würzburg - D)
Chairperson: Fabrizio Pane (Naples - I)
Speaker: Leif Bergsagel (Scottsdale - USA)
16.20 The role of consolidation and maintenance in young patients
Alessandro Corso (Pavia - I)
Workshop 1 - Immunobiology of multiple myeloma: a translational view Chairpersons: Francesco Annunziato (Florence - I), Ennio Carbone (Catanzaro- I) 16.40Upfront therapy in elderly patients
Francesca Patriarca (Udine - I)
15.00T cell-mediated immunity
Ivan Borrello (Baltimore - USA)
17.00Allogeneic stem cell transplantation
Francesco Onida (Milan - I)
15.20 NK cell-mediated immunosurveillance
Angela Santoni (Rome - I)
17.20 - 17.40 Coffee break
15.40 PD1 and Treg
Workshop 7 - Relapsed/refractory myeloma
Massimo Massaia (Turin - I)
Chairpersons: M
assimo Martino (Reggio Calabria - I), Maurizio Musso (Palermo - I)
16.00Role of interleukin-17 in the progression from asymptomatic to symptomatic
17.40Can multiple myeloma become a chronic disease?
multiple myeloma
Joan Bladé (Barcelona - E)
Matteo Bellone (Milan - I)
18.00Personalized therapy for the relapsed/refractory patient
16.20Myeloid-derived suppressor cells
Fortunato Morabito (Cosenza - I)
Kim de Veirman, Karin Vanderkerken (Brussels - B)
18.20Supportive care in multiple myeloma: pain/breakthrough pain, cytopenia, emesis
16.40 - 17.00 Coffee break
Giuseppe Longo (Taormina - I)
Workshop 2 - Immunodeficiency and infections: a path for evidence18.40Daratumumab alone or in combination in relapsed multiple myeloma
based supportive care
Henk Lokhorst (Utrecht - NL)
Chairpersons: Francesco Silvestris (Bari - I), Carlo Torti (Catanzaro - I)
17.00Humoral deficiency in multiple myeloma: the multifaceted picture
Isabella Quinti (Rome - I)
UNDER THE PATRONAGE OF
Società Italiana di Ematologia
CONGRESS VENUE
UNIVERSITY MAGNA GRAECIA
Viale Europa - Germaneto, Catanzaro (Italy)
www.unicz.it
17.20Invasive mycosis in multiple myeloma in the era of novel therapies
Giuseppe Gentile (Rome - I)
SIICA SECRETARIAT
17.40Antimicrobial prophylaxis in multiple myeloma: is there a rationale?
Igor Blau (Berlin - D)
Rita Repizzi
Tel. +39 333 4398196
[email protected]
www.siica.org
18.00Substitutive immunoglobulins therapy in immunoparetic patients
Roberto Ria (Bari - I)
18.20Welcome Cocktail
More information
www.siica.org
Local DMC
ORGANIZING SECRETARIAT
& PROVIDER
meeting
specialists
Via XX Settembre, 42
88100 Catanzaro
Viale G. Matteotti, 7
50121 Florence, Italy
Tel. +39 055 50351
Fax +39 055 5001912
[email protected]